Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

PPI effectively attenuates acid-related dyspepsia

29 Jun 2019

Monotherapy with a proton pump inhibitor appears to be effective in the treatment of functional dyspepsia (FD) symptoms associated with gastro-oesophageal reflux disease (GERD), according to a study.

The study included 233 patients (mean age, 56.5 years; 58 percent male; mean body mass index, 23.7 kg/m2) with FD and GERD, among whom 40 had mild, 151 had moderate and 42 had severe GERD symptoms. All patients were given PPI treatment for 4 weeks after endoscopy, and the severity of the symptoms and responses to treatment were evaluated prior to and after 4 weeks of treatment using the Gastroesophageal Reflux and Dyspepsia Therapeutic Efficacy and Satisfaction Test (GERD-TEST).

In the entire population, the pretreatment scores for the symptoms recorded were as follows: 3.7 for GERD-symptom subscale (SS), 3.3 for FD-SS, 3.6 for FD-epigastric pain syndrome symptom, and 3.0 for FD-postprandial distress-SS.

Analysis of the pretreatment scores for each symptom showed that a higher GERD-SS score was significantly associated with higher scores on any kind of FD score.

Furthermore, 4 weeks of PPI treatment led to a significant reduction in any of GERD/FD symptoms. Changes in the score for each symptom were markedly greater in the group of patients with more severe GERD-SS.

In light of the present data, PPI monotherapy may be considered the treatment of choice in patients with FD and more severe GERD symptom, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.